The main customers are private and public hospitals and healthcare institutions, both in Italy and Europe, especially the departments of ICU, hematology-infectivology (immunocopromized patients), pneumology, medicine, emergency and first-aid departments, ambulance, cardiology, neonatology. DIMAR forecasts a very fast growth in terms of revenues, EBIT and employment through the marketing of DI-CO2 technology in all its medical devices applications, and the resulting sales increase of all NIV-associated products, such as helmets, masks, accessories and equipment, which represent the main business area for DIMAR at the moment.
With DI-CO2, DIMAR will be the first company in the world to offer a system which is able to monitor the total eliminated CO2 in a highly reliable way. 80% of corporate profits are invested annually in R & D laboratory, which is provided with state-of-art and cutting-edge equipment. Thanks to the high level of technology, Dimar laboratory is made available to university researchers for the study and tests of specific and complex clinical projects.